The purpose of this study is to determine if it is feasible, safe, and effective to use Cyberknife radiotherapy to deliver partial breast radiotherapy after lumpectomy.Patients meeting eligibility criteria will be invited to participate. Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions. Short-term and long-term toxicity will be assessed as well as Tumor control and site of failure (if any).
This study will determine the feasibility and toxicity of a short course of accelerated radiotherapy as adjuvant treatment for early stage breast cancer. Successful completion of this project may provide a rationale to offer this treatment for select patients with the benefit of potentially less tissue damage and a shorter overall course of therapy. These improvements may ultimately allow more patients the opportunity of breast conserving therapy to treat their cancer
Diagnosis of breast malignancy, stage T1 Surgical treatment with lumpectomy age 60 or older resection margins negative by at least 2mm any grade ER positive unicentric invasive ductal pathologic free of nodal metastases (N0, i- or i+) Post-lumpectomy cavity to whole breast ratio must be less than or equal to 30%
Exclusion criteria
Prior radiotherapy to the breast Neoadjuvant chemotherapy multicentric disease Pure DCIS histology Presence of extensive intraductal component Node positive disease (N1 or greater)
